search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


Epilepsy, anti-epileptic drugs and osteoporosis: prevalence of osteoporosis in adults with epilepsy.
Epilepsie, anti-epileptica en botontkalking: een onderzoek naar hoe vaak botontkalking voorkomt onder volwassenen met epilepsie.



- candidate number6495
- NTR NumberNTR2020
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR19-sep-2009
- Secondary IDs09-N-62 METC Atrium MC Parkstad
- Public TitleEpilepsy, anti-epileptic drugs and osteoporosis: prevalence of osteoporosis in adults with epilepsy.
Epilepsie, anti-epileptica en botontkalking: een onderzoek naar hoe vaak botontkalking voorkomt onder volwassenen met epilepsie.
- Scientific TitleEpilepsy, anti-epileptic drugs and osteoporosis: prevalence of osteoporosis in adults with epilepsy, a retrospective study in Atrium Medical Centre Parkstad.
- ACRONYMEPANOS
- hypothesisChronic use of anti-epileptic drugs is associated with low bone mineral density. However, not for all anti-epileptic drugs this associatjon has been found. To determine the prevalence of osteopenia and osteoporosis all adult patients with epilepsy and anti-epileptic drugs are screened with dual-energy X-ray absorptiometry for the presence of osteoporosis. In the literature the prevalence varies between 20-75%, depending on the population studied. The investigators expect to find an increased prevalence of osteoporosis in the adult patients with epilepsy who are visiting the outpatient department Neurology of the Atrium Medisch Centrum .
- Healt Condition(s) or Problem(s) studiedOsteoporosis, Antiepileptics, Epilepsy, Bone Metabolism
- Inclusion criteria1. Adults >= 18 years;
2. Diagnosis of epilepsy;
3. Current treatment wit anti-epileptic drugs.
- Exclusion criteria1. No dual-energy X-ray absorptiometry;
2. No determination of calcium, 25-hydroxy vitamin D, alkaline phosphatase and parathormone.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 1-jan-2010
- planned closingdate1-jan-2012
- Target number of participants50
- InterventionsN/A
- Primary outcomeT-score DEXA scan.
- Secondary outcome1. Association between bone mineral density and use of type of anti-epileptic drug(s);
2. Association between bone mineral density and number of anti-epileptic drugs and dosage.
- TimepointsN/A
- Trial web siteN/A
- statusplanned
- CONTACT FOR PUBLIC QUERIESDrs. K. Beerhorst
- CONTACT for SCIENTIFIC QUERIESDrs. K. Beerhorst
- Sponsor/Initiator Atrium Medisch Centrum Parkstad
- Funding
(Source(s) of Monetary or Material Support)
Atrium Medisch Centrum Parkstad
- PublicationsN/A
- Brief summaryEpilepsy, anti-epileptic drugs and osteoporosis: prevalence of osteoporosis in adults with epilepsy (EPANOS).

Chronic use of anti-epileptic drugs (AEDs) is associated with low bone mineral density. However, not for all anti-epileptic drugs this association has yet been found.

To determine the prevalence of osteopenia and osteoporosis in adult patients with epilepsy and anti-epileptic drugs (who are visiting the outpatient department Neurology of the Atrium Medisch Centrum) by measurement of the bone mineral density with dual-energy X-ray absorptiometry (DEXA-scan). The primary outcome is the T-score of the DEXA-scan. Moreover we also investigate if there is any association between the bone mineral density and the type of anti-epileptic drug(s) used (enzyme-inducing vs non-enzyme-inducing AEDs), the number of anti-epileptic drugs or the dosage of these drugs. We expect to find an increased prevalence of osteoporosis in the adult patients with epilepsy who are visiting the outpatient department Neurology of the Atrium Medisch Centrum.
- Main changes (audit trail)
- RECORD19-sep-2009 - 29-okt-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl